Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.

Technology: general issues --- History of engineering & technology --- Materials science --- poly(lactic-co-glycolic acid) (PLGA) --- blood–brain barrier (BBB) --- current Good Manufacturing Practice (cGMP) --- Food and Drug Administration (FDA) --- nanotechnology --- PLGA nanoparticles --- neurodegenerative diseases --- drug delivery --- central nervous system --- neuroprotective drugs --- fluorescent labeling --- DiI --- coumarin 6 --- rhodamine 123 --- Cy5.5 --- quantum yield --- brightness --- stability of fluorescent label --- confocal microscopy --- intracellular internalization --- in vivo neuroimaging --- double-emulsion method --- dry powder inhalation --- antigen release --- porous PLGA particles --- microfluidics --- methotrexate --- chitosan --- PLA/PLGA --- sustained release --- micro-implant --- animal model --- minimally invasive --- drug delivery system --- nanoparticles --- poly (lactic-co-glycolic acid) (PLGA) --- microfluidic --- pharmacokinetics (PK) and biodistribution --- atorvastatin calcium --- poly(lactide-co-glycolide) --- polymeric nanoparticles --- carrageenan induced inflammation --- anti-inflammatory --- radiolabeled nanoparticles --- nuclear medicine --- photothermal therapy --- phthalocyanine --- SKOVip-kat --- Katushka --- TurboFP635 --- JO-4 --- PLGA --- orthotopic tumors --- 3D culture --- spheroids --- poly(lactic-co-glycolic acid) --- nanomedicine --- scale-up manufacturing --- clinical translation --- inline sonication --- tangential flow filtration --- lyophilization --- downstream processing --- H. pylori --- design of experiments --- poly(lactic-co-glycolic) acid --- size --- cancer --- chemoimmunotherapy --- immunogenic cell death --- immune checkpoint blockade --- PNA5 glycopeptide --- mas receptor --- angiotensin --- PLGA diblock copolymer --- ester and acid-end capped --- double emulsion solvent evaporation --- biocompatible --- biodegradable --- cardiovascular --- nanoparticle --- solid-state characterization --- in vitro --- drug release kinetics modeling --- PEGylation --- amine --- emulsion --- polyvinyl alcohol (PVA) --- Pluronic triblock copolymer --- trehalose --- sucrose --- Indomethacin --- solvents --- stabilizers --- morphology --- particle-size --- encapsulation --- drug release --- cytotoxicity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.

Technology: general issues --- History of engineering & technology --- Materials science --- poly(lactic-co-glycolic acid) (PLGA) --- blood–brain barrier (BBB) --- current Good Manufacturing Practice (cGMP) --- Food and Drug Administration (FDA) --- nanotechnology --- PLGA nanoparticles --- neurodegenerative diseases --- drug delivery --- central nervous system --- neuroprotective drugs --- fluorescent labeling --- DiI --- coumarin 6 --- rhodamine 123 --- Cy5.5 --- quantum yield --- brightness --- stability of fluorescent label --- confocal microscopy --- intracellular internalization --- in vivo neuroimaging --- double-emulsion method --- dry powder inhalation --- antigen release --- porous PLGA particles --- microfluidics --- methotrexate --- chitosan --- PLA/PLGA --- sustained release --- micro-implant --- animal model --- minimally invasive --- drug delivery system --- nanoparticles --- poly (lactic-co-glycolic acid) (PLGA) --- microfluidic --- pharmacokinetics (PK) and biodistribution --- atorvastatin calcium --- poly(lactide-co-glycolide) --- polymeric nanoparticles --- carrageenan induced inflammation --- anti-inflammatory --- radiolabeled nanoparticles --- nuclear medicine --- photothermal therapy --- phthalocyanine --- SKOVip-kat --- Katushka --- TurboFP635 --- JO-4 --- PLGA --- orthotopic tumors --- 3D culture --- spheroids --- poly(lactic-co-glycolic acid) --- nanomedicine --- scale-up manufacturing --- clinical translation --- inline sonication --- tangential flow filtration --- lyophilization --- downstream processing --- H. pylori --- design of experiments --- poly(lactic-co-glycolic) acid --- size --- cancer --- chemoimmunotherapy --- immunogenic cell death --- immune checkpoint blockade --- PNA5 glycopeptide --- mas receptor --- angiotensin --- PLGA diblock copolymer --- ester and acid-end capped --- double emulsion solvent evaporation --- biocompatible --- biodegradable --- cardiovascular --- nanoparticle --- solid-state characterization --- in vitro --- drug release kinetics modeling --- PEGylation --- amine --- emulsion --- polyvinyl alcohol (PVA) --- Pluronic triblock copolymer --- trehalose --- sucrose --- Indomethacin --- solvents --- stabilizers --- morphology --- particle-size --- encapsulation --- drug release --- cytotoxicity --- poly(lactic-co-glycolic acid) (PLGA) --- blood–brain barrier (BBB) --- current Good Manufacturing Practice (cGMP) --- Food and Drug Administration (FDA) --- nanotechnology --- PLGA nanoparticles --- neurodegenerative diseases --- drug delivery --- central nervous system --- neuroprotective drugs --- fluorescent labeling --- DiI --- coumarin 6 --- rhodamine 123 --- Cy5.5 --- quantum yield --- brightness --- stability of fluorescent label --- confocal microscopy --- intracellular internalization --- in vivo neuroimaging --- double-emulsion method --- dry powder inhalation --- antigen release --- porous PLGA particles --- microfluidics --- methotrexate --- chitosan --- PLA/PLGA --- sustained release --- micro-implant --- animal model --- minimally invasive --- drug delivery system --- nanoparticles --- poly (lactic-co-glycolic acid) (PLGA) --- microfluidic --- pharmacokinetics (PK) and biodistribution --- atorvastatin calcium --- poly(lactide-co-glycolide) --- polymeric nanoparticles --- carrageenan induced inflammation --- anti-inflammatory --- radiolabeled nanoparticles --- nuclear medicine --- photothermal therapy --- phthalocyanine --- SKOVip-kat --- Katushka --- TurboFP635 --- JO-4 --- PLGA --- orthotopic tumors --- 3D culture --- spheroids --- poly(lactic-co-glycolic acid) --- nanomedicine --- scale-up manufacturing --- clinical translation --- inline sonication --- tangential flow filtration --- lyophilization --- downstream processing --- H. pylori --- design of experiments --- poly(lactic-co-glycolic) acid --- size --- cancer --- chemoimmunotherapy --- immunogenic cell death --- immune checkpoint blockade --- PNA5 glycopeptide --- mas receptor --- angiotensin --- PLGA diblock copolymer --- ester and acid-end capped --- double emulsion solvent evaporation --- biocompatible --- biodegradable --- cardiovascular --- nanoparticle --- solid-state characterization --- in vitro --- drug release kinetics modeling --- PEGylation --- amine --- emulsion --- polyvinyl alcohol (PVA) --- Pluronic triblock copolymer --- trehalose --- sucrose --- Indomethacin --- solvents --- stabilizers --- morphology --- particle-size --- encapsulation --- drug release --- cytotoxicity